Searched for
MANKIND PHARMA FINANCIAL GROWTH
Mankind Pharma Q2 profit rises 38% to Rs 716 croreMankind Pharma has announced a profit increase of 37.7% to ₹716 crore during the September quarter. Revenue from operations rose to ₹4,337....- Tesla India sees robust profit and revenue growth in FY26Tesla India Motors and Energy achieved revenue of ₹247.3 crore and a net profit of ₹5.2 crore in FY26. Vehicle sales constituted nearly 87%...
- Mankind Pharma shares key business developments from Q2 & H1 of FY27The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...
- Auto sector margins may improve from third quarter but El Nino, West Asia crisis key risks: ReportAutomobile sector margins are projected to improve gradually after the second quarter of FY27 as manufacturers increase prices. The growth ...
- Coforge slips 3% even as Jefferies, Nomura, others raise targets after Q2 earnings. Why are they bullish?Coforge shares fell despite strong Q2 results and brokerages raising target prices. Net profit surged 56.5% year-on-year to Rs 588.1 crore,...
- IndusInd Bank shares rise 2% after Q2 results. Why Jefferies cut target price despite lender swinging to profitIndusInd Bank announced a net profit of Rs 1,176 crore for the quarter ending September 2027. The bank's asset quality improved with gross ...
- Double-digit growth seen on corporate scoreboard in Q2, but bank, IT, pharma lagSeptember quarter earnings exhibited significant revenue and profit growth for various companies in key sectors. Revenue rose by 22.1% with...
- Stocks in news: Infosys, Kotak Mahindra Bank, YES Bank, Raymond, BPCL, Coforge and Senco GoldIndian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...
- Kotak Mahindra Bank Q2 results: Consolidated PAT rises 26% YoY to Rs 5,645 crore; NII up 16%Kotak Mahindra Bank has announced an impressive 26% year-on-year increase in consolidated profit after tax for the second quarter, highligh...
- Apple India revenue grows 32% to cross Rs 1 lakh crore mark in FY26"Apple India Private Limited provides and markets Apple brand products and software, and reported its revenues for the financial year 2025-...
- Indian pharma: Unethical practices, marketing rules under lens; new review body set upThe review comes against the backdrop of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which was introduced in 2015 as a...
- ETMarkets Smart Talk| A ₹25,000 monthly SIP can grow to ₹2.17 crore in 15 years—with a 10% annual step-up: Jeet MarwadiIn an interview with Kshitij Anand of ETMarkets, Jeet Marwadi, Founder and Managing Director of 1 Finance, explains why reviewing loans, in...
- Sun Pharma falls short of bond fundraising target amid rising yieldsSun Pharma successfully secured ₹7,816 crore in its latest fundraising round, yet it fell short of its ambitious ₹10,000-crore target. The ...
- Former Mumbai office boy wins tax battle over Rs 1.46 crore transactions linked to alleged KYC misuseIn a significant legal battle, former office boy Waghela challenged a disputed tax order linked to dubious financial practices. The Income ...
- Tata Motors CV Q2 Results Preview: Profit may rise up to 44% YoY, revenue 45%; margins, volume growth in focusTata Motors Commercial Vehicles is expected to post strong Q2FY27 revenue and profit growth, driven by 43% volume expansion. However, risin...
- Varmora Granito H1 profit jumps 498% to Rs 53.7 cr; shares rise nearly 6%Varmora Granito Ltd reported a 498 percent growth in profit after tax for the first half of the fiscal year. They saw a 3.3 percent rise in...
- ETMarkets Smart Talk| India’s next wealth creators may be hidden in specialised manufacturing and energy infrastructure: Paresh BhagatParesh Bhagat, Chairman of Mangal Keshav Financial Services, discusses where India’s next wealth creators could emerge from, why several mi...
- Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select playersIndia's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...
- Stocks in news: RIL, Wipro, Jio Financial, Tata Communications, YES Bank, PNBFrom a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
Load More
